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Objectives: To identify patterns of variation in breast cancer mortality in Europe (1980e2010), using a
model-based approach.
Methods: Mortality data were obtained from the World Health Organization database and mixed models
were used to describe the time trends in the age-standardized mortality rates (ASMR). Model-based
clustering was used to identify clusters of countries with homogeneous variation in ASMR.
Results: Three patterns were identiﬁed. Patterns 1 and 2 are characterized by stable or slightly increasing
trends in ASMR in the ﬁrst half of the period analysed, and a clear decline is observed thereafter; in
pattern 1 the median of the ASMR is higher, and the highest rates were achieved sooner. Pattern 3 is
characterised by a rapid increase in mortality until 1999, declining slowly thereafter.
Conclusion: This study provides a general model for the description and interpretation of the variation in
breast cancer mortality in Europe, based in three main patterns.
 2013 Elsevier Ltd. All rights reserved.Introduction
Breast cancer is the leading cause of oncological death among
women, in both economically developed and developing settings.1
In Europe, in the last decades the mortality decreased in most
countries,2 along with rising incidence rates.3
An increasing incidence may be explained by trends towards a
more frequent exposure to factors that contribute to a higher risk of
breast cancer (e.g.: delayed childbearing, lower parity, use of
postmenopausal hormone therapy, obesity, physical inactivity),4,5
while the widespread use of mammographic screening further
contributes to higher incidence rates.5,6
The decline in mortality rates has been attributed both to an
increasing frequency of early diagnosis through mammography
screeningandaccess tomore efﬁcient treatments, including adjuvant
chemotherapy or tamoxifen, besides improved radiotherapy and
surgery.7e11 The identiﬁcation of clusters of countries with similar
trends in breast cancer mortality may contribute to understand theda Universidade do Porto,
reditiva e Saúde Pública, Al.
: þ351 225513652; fax: þ351
All rights reserved.impact, at a population level, of early detection and improveddisease
management. Previous attempts to describe breast cancer mortality
patterns relied on criteria related to geographical,12 social, economic
or cultural13e15 characteristics. Model-based clustering may allow a
more meaningful grouping of the different settings with no a priori
constraints, according to the magnitude of the mortality rates at
onset of the observation period, as well as its trends.
Therefore, we aimed to identify patterns of variation in breast
cancer mortality, using a model-based approach.Methods
Breast cancer mortality data were obtained for 40 countries
from the World Health Organization (WHO) database updated in
November 24, 2011.16 Albania, Bosnia and Herzegovina, Cyprus,
Montenegro, The Former Yugoslav Republic of Macedonia, Serbia
and Slovakia had data available for less than 20 calendar years
between 1980 and 2010, and were excluded from our analyses
(Fig. 1). In this period, different revisions of the International
Classiﬁcation of Diseases (ICD) were used; we extracted the num-
ber of deaths, corresponding to the codes A054 (ICD-8), B113 (ICD-
9), C50 (ICD-10).
Mid-year estimates of the resident population were obtained
from the 2010 revision of United Nations World Population
*Finland, France, Greece and Sweden had substantially higher GDP than the other countries included in pattern 3, 
and were treated separately to increase the homogeneity of this cluster
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Fig. 1. Flowchart of the model-based approach used to identify breast cancer mortality patterns.
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(ASMR) for all ages, by the direct method, using the world standard
population18 as reference.
Mixed models19 were used to describe the time trends in the
ASMR, including random terms by country, for the intercept and for
slope, quadratic and cubic terms. Iceland presented values three
times the interquartile range above or below the median for at least
one of the above coefﬁcients and was excluded from further ana-
lyses (Fig. 1). These models were used to estimate the ASMR for the
years with missing data, between 1980 and 2010 (Appendix 1).Model-based clustering20 was used to identify groups of
countries that share similar time trends in the ASMR, while dis-
tinguishing them from other homogeneous groups of countries
regarding the variation in mortality rates. According to this
method, the data (intercept, slope, quadratic and cubic terms) are
assumed to have a multivariate normal distribution, parameterized
by their means and covariances, generated by clusters. The geo-
metric features (orientation, volume and shape) of the distribu-
tions are estimated from the data, and can be allowed to vary
between clusters, or constrained to be the same for all clusters.21
Table 1
Characterization of the female breast cancer mortality patterns regarding the esti-
mated age-standardized mortality rates (direct method, world standard popula-
tion), all ages (ASMR), in 1980, 1995 and 2010, percent changes in rates in the
periods 1980e1995 and 1995e2010, and highest rates and corresponding year
observed between 1980 and 2010.
Median (percentile 25; percentile 75)
Pattern 1 Pattern 2 Pattern 3a
ASMRb
1980 25.5 (24.7; 26.5) 19.2 (16.8; 20.0) 12.7 (10.7; 14.2)
1995 25.5 (23.4; 26.4) 20.7 (18.2; 21.4) 16.0 (15.8; 17.6)
2010 17.4 (15.9; 18.0) 15.1 (14.1; 16.1) 15.8 (14.7; 16.1)
Variation in
ASMR (%)c
1980e1995 3.3 (7.7; 0.6) 8.0 (4.8; 14.6) 33.3 (24.9; 47.9)
1995e2010 31.3
(32.6; 30.4)
23.9
(24.9; 22.7)
7.2
(12.8; 2.2)
ASMRd
Higher value
observed
29.5 (27.3; 30.0) 22.1 (19.9; 22.5) 18.2 (16.5; 19.6)
Year of
highest value
1986.5
(1985.5; 1991.5)
1993 (1991; 1994) 1999 (1994; 2002)
ASMR e Age standardized mortality rates (world standard population).
a The results referring to pattern 3 do not include data from Finland, France,
Greece or Sweden.
b Model estimates.
c Computed from the model estimates.
d Observed data.
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for the most homogeneous grouping of countries regarding their
patterns of variation, as assessed by visual inspection of the
country-speciﬁc trends, selected among those with the lowest
Bayesian Information Criterion (BIC)22 (Appendix 2).
To describe the patterns of variation that characterize each
cluster, we computed the means of the predicted country-speciﬁc
ASMR for each of the clusters identiﬁed, for every year within the
period 1980e2010, and represented them graphically; for each
cluster we also presented the median and percentile 25 and 75 of
the rates in the beginning, middle and end of the period under
analysis, as well as the percent variation in ASMR in the ﬁrst and
second half of the same period.
Data analysis was conducted using data from 33 European
countries (Fig. 1), with the software R 2.14.1, using the packages
nlme23 and mclust24 for mixed models analysis and model-based
clustering, respectively.
The patterns identiﬁed through themodel-based approachwere
further characterized according to gross domestic product (GDP)
per capita in 1995 (the midpoint of the period under analysis); data
were obtained from the World Bank database.25
Data on organized breast cancer screening activities in each
country were obtained from published peer reviewed articles or
ofﬁcial reports and used in the interpretation of the patterns,
along with the trends in breast cancer incidence (Appendix 3).
Age-standardized (world standard population) incidence rates
(ASIR), and the corresponding standard errors, were abstracted
from the Cancer Incidence in Five Continents database CI5plus,
after the November 5, 2012 update,26 for all the years with
available data in the period 1970e2002; data were available for 18
of the European countries eligible for model-based clustering. We
analysed trends in incidence rates for the age groups covered by
the breast cancer screening programmes implemented in each
country, if applicable, or the age group 50e69 years (deﬁned ac-
cording to European Council’s guidelines for breast cancer
screening27), as well as for the younger and older women than
those eligible for screening. The annual percent change (APC), as
well as signiﬁcant changes in the linear trends of age-
standardized incidence rates were assessed using the software
Joinpoint Regression Program, version 3.5.3.28 The number of
joinpoints allowed was limited to a maximum of ﬁve (Table 2). For
the United Kingdom (UK), incidence data were available only for
Scotland and England.
Results
We identiﬁed three main patterns of breast cancer mortality
trends in Europe, hereafter referred to as patterns 1, 2 and 3.
Patterns 1 and 2 are characterized by stable or slightly
increasing trends in ASMR in the ﬁrst half of the period under
analysis, and a clear decline was observed thereafter; however, the
median of the ASMR was higher for the countries included in
pattern 1, throughout the whole period, and the highest rates were
achieved sooner than in pattern 2. Pattern 1 comprises mostly
countries fromwestern and northern Europe, and all of themwere
high income countries [median GDP (USD): 27584, range: 9457e
50600], while pattern 2 is more heterogeneous regarding the
geographical distribution and GDP [median GDP (USD): 15151,
range: 4411e34156] (Figs. 1 and 2 and Table 1).
Pattern 3 included 11 countries with GDP lower than 5000
USD, mainly eastern and northern European, and four countries
(Finland, France, Greece and Sweden) with GDP higher than
12000 USD (Fig. 1). The former were characterized by the lowest
median ASMR in 1980, which increased steeply during the ﬁrst
half of the period under analysis, and decreased thereafter,mostly after 1999 and at a slower pace than in patterns 1 and 2
(Fig. 2 and Table 1). Finland, France and Greece depicted slightly
increasing trends in the ﬁrst part of the period under study and a
marked decline from that point onwards, resembling more
closely patterns 1 and 2. However, in these countries the ASMR
observed in 1980 were among the lowest in Europe (Appendix 1).
Sweden presented a downward trend throughout the whole
period, with a steeper decrease in the second half, which is a
unique behaviour among all the countries analysed (Appendix 1).
Therefore, these four countries were treated separately from all
other included in pattern 3, to increase the homogeneity of this
cluster.
Over the last three decades there was a levelling of breast cancer
mortality across Europe. In 1980 the median of the ASMR in the
countries included in pattern 3 (excluding Finland, France, Greece
and Sweden) was approximately half the observed for pattern 1,
but only 10% lower in 2010 (Table 1).
Most of the countries included in patterns 1 and 2 have orga-
nized screening programmes, which were initiated before 1995 in
more than half of those grouped in pattern 1 and in more than one
third of those in pattern 2. Nearly two-thirds of the countries
included in pattern 3 (excluding Finland, France, Greece and Swe-
den) had no organized screening implemented. Finland, France,
Greece and Sweden had organized screening (Fig. 3).
In the age groups eligible for screening, among the countries
with screening programmes implemented before 2002 (the last
year with available date in CI5plus) there was a steep increase in
the ASIR close to the year of screening onset, reﬂecting the
increased detection of prevalent cancers, for England, Finland, the
Netherlands, Norway, Scotland and Sweden; these countries
started organized screening mostly in the 1980’s and all have a
participation rate of over 70%.29,30 A similar increase was
observed in Italy after 1995; despite having a screening pro-
gramme implemented for the ﬁrst time in 1985, only since 1996
the Italian Ministry of Health issued a nationally agreed proto-
col.31 In the remaining countries the ASIR increased with time in
all countries considered for this analysis, regardless of the exis-
tence of organized screening (Table 2).
Table 2
Characterization of countries regarding trends in age-standardized incidence rates by age groups, according to patterns of trends in breast cancer mortality rates.
Country Age groupsb ASIRa Trends in ASIRa
(Years) 1988 2002 Period 1
APC (95%CI)
Period 2
APC (95%CI)
Period 3
APC (95%CI)
Period 4
APC (95%CI)
Period 5
APC (95%CI)
Period 6
APC (95%CI)
Pattern 1 Denmark 0e49 32.0 28.4 1970e1988 1988e2002
1.7 (1.1 to 2.3) 1.1
(1.8 to 0.4)
50e59 210.7 264.6 1970e2002
1.9 (1.7 to 2.1)
60þ 272.9 378.6 1970e1986 1986e2002
0.9 (0.4 to 1.5) 2.5 (2.0 to 3.0)
England (UK) 0e49 27.1 29.5 1985e1992 1992e2002
1.8 (1.0 to 2.6) 0.2 (0.2 to 0.6)
50e64 196.2 288.5 1985e1988 1988e1991 1991e1994 1994e2002
2.3 (1.3 to 6.0) 12.6
(5.5 to 20.1)
3.4
(9.1 to 2.6)
2.2 (1.5 to 2.8)
65þ 256.1 302.7 1985e2002
1.0 (0.7 to 1.2)
The Netherlands 0e49 29.2 39.4 1973e2002
1.1 (0.8 to 1.4)
50e69 203.8 319.0 1973e1991 1991e1995 1995e2002
0.8 (0.2 to 1.9) 7.5 (6.1 to 23.0) 0.4
(3.4 to 2.7)
70þ 296.7 347.2 1973e2002
1.6 (1.0 to 2.1)
Scotland (UK) 0e49 26.7 26.8 1975e2002
0.3 (0.1 to 0.5)
50e64 188.0 288.1 1975e1988 1988e1991 1991e2002
1.2 (0.5 to 1.9) 12.1
(0.6 to 26.4)
0.8 (0.1 to 1.6)
65þ 254.7 271.9 1975e2002
1.0 (0.9 to 1.2)
Switzerland 0e49 23.7 26.3 1983e2002
0.6 (0.0 to 1.3)
50e70 221.6 298.7 1983e2002
3.1 (2.4 to 3.8)
70þ 304.5 258.2 1983e2002
0.9
(1.6 to 0.3)
Pattern 2 Austria 0e49 22.0 24.6 1988e2002
0.9 (0.3 to 2.0)
50e69 199.3 244.5 1988e2002
1.9 (1.2 to 2.7)
70þ 317.6 356.2 1988e2002
1.0 (2.5 to 0.7)
Czech Republic 0e44 9.9 10.1 1983e2002
0.3 (0.3 to 0.9)
45e69 126.5 182.5 1983e2002
2.4 (2.1 to 2.7)
70þ 192.7 280.9 1983e1995 1995e2002
3.6 (2.8 to 4.4) 0.7 (0.8 to 2.2)
Germany 0e49 25.2 28.1 1970e2002
1.0 (0.7 to 1.4)
50e69 202.7 272.1 1970e1987 1987e2002
0.6 (0.2 to 1.4) 2.9 (2.1 to 3.8)
70þ 248.9 317.4 1970e2002
1.8 (1.5 to 2.1)
Italy 0e49 29.1 36.5 1988e2002
2.1 (1.6 to 2.6)
50e69 198.3 293.4 1988e1995 1995e1999 1999e2002
2.5 (0.5 to 4.5) 7.5 (0.9 to 14.5) 2.5
(8.2 to 3.6)
70þ 247.1 282.9 1988e1991 1991e1995 1995e1999 1999e2002
0.7 (2.8 to 1.6) 3.7 (1.8 to 5.8) 1.8 (0.0 to 3.5) 2.8
(4.4 to 1.1)
Norway 0e49 21.7 23.1 1970e1996 1996e2002
1.3 (0.9 to 1.6) 2.2
(4.7 to 0.4)
50e69 165.5 287.1 1970e1990 1990e2002
0.8 (0.2 to 1.4) 5.0 (3.9 to 6.0)
70þ 262.0 233.7 1970e1985 1985e2002
2.2 (1.5 to 2.9) 0.3
(0.8 to 0.2)
Spain 0e49 20.8 26.3c 1985e2000
2.4 (1.8 to 3.1)
(continued on next page)
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Table 2 (continued )
Country Age groupsb ASIRa Trends in ASIRa
(Years) 1988 2002 Period 1
APC (95%CI)
Period 2
APC (95%CI)
Period 3
APC (95%CI)
Period 4
APC (95%CI)
Period 5
APC (95%CI)
Period 6
APC (95%CI)
50e64 120.3 211.0c 1985e2000
3.2 (2.4 to 3.9)65þ 157.9 193.4c 1985e2000
2.1 (1.4 to 2.7)
Slovenia 0e49 18.4 21.8 1970e2002
1.3 (0.9 to 1.6)
50e69 152.8 205.7 1970e2002
2.4 (2.2 to 2.7)
70þ 197.7 259.0 1970e2002
3.1 (2.8
to 3.4)
Pattern 3 Estonia 0e49 16.4 21.0 1970e2002
1.7 (1.3 to 2.1)
50e59 103.0 154.5 1970e2002
2.2 (1.8 to 2.6)
60þ 105.6 170.1 1970e2002
2.9 (2.6 to 3.2)
Finland 0e49 24.1 27.1 1970e1995 1995e2002
2.6 (2.4 to 2.9) 0.6
(2.0 to 0.8)
50e59 200.7 316.7 1970e1984 1984e1989 1989e1993 1993e2002
2.2 (1.5 to 2.9) 7.7 (3.7 to 11.9) 0.2 (5.3 to 6.0) 4.4 (3.5 to 5.3)
60þ 229.7 289.7 1970e2002
1.9 (1.6 to 2.1)
France 0e49 32.5 32.1 1983e1994 1994e2002
2.8 (4.0 to 1.5)
2.6 (1.7 to 3.6)
50e74 229.5 361.7 1983e2002
2.9 (2.5 to 3.4)
75þ 240.7 277.7 1983e2002
1.2 (0.7 to 1.7)
Latvia 0e49 16.6 17.3 1988e2002
1.5 (0.2 to 2.8)
50e69 111.0 153.8 1988e2002
3.0 (2.4 to 3.6)
70þ 83.2 153.3 1988e2002
5.4 (3.9 to 6.9)
Lithuania 0e49 16.3 16.8 1978e2002
1.3 (0.9 to 1.8)
50e69 95.8 136.1 1978e2002
2.9 (2.5 to 3.4)
70þ 83.3 156.6 1978e2002
4.4 (3.8 to 5.0)
Poland 0e49 18.1 19.6 1988e1995 1995e2002
3.4 (1.1 to 5.8) 1.6
(3.6 to 0.5)
50e69 130.5 200.2 1988e2002
3.0 (2.3 to 3.7)
70þ 169.2 209.0 1988e1995 1995e2002
4.9 (1.2 to 8.8) 1.8
(4.6 to 1.1)
Sweden 0e49 25.3 25.9 1970e2002
0.9 (0.8 to 1.1)
50e69 209.4 302.6 1970e1978 1978e1986 1986e1990 1990e1993 1993e2002
2.1 (1.3 to 2.8) 0.0 (0.9 to 0.9) 8.8 (5.5 to 12.3) 2.4
(8.0 to 3.5)
3.0 (2.5 to 3.5)
70þ 288.9 282.5 1970e1973 1973e1979 1979e1984 1984e1987 1987e1995 1995e2002
2.4
(6.9 to 2.5)
3.0 (1.0 to 5.0) 2.4
(4.9 to 0.1)
3.5 (4.4 to 12.1) 1.5
(2.5 to 0.5)
1.3 (0.2 to 2.3)
a ASIR e age-standardized incidence rates (world standard population).
b Three groups were considered: age groups covered by the organized breast cancer screening implemented in each country; age groups below the ages eligible for
screening; age groups above the ages eligible for screening. In countries with no organized programme(s), the recommendations of the European Council’s guidelines were
considered as reference (50e69 years).
c Age-standardized incidence rates in the last year with data available (2000).
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We identiﬁed three patterns that summarize the temporal
trends in breast cancer mortality across European countries.
Despite an overall downward trend observed in recent years
throughout Europe, the patterns differ in the highest rates achievedand the year of inﬂection in the ASMR trends. A levelling of breast
cancer mortality was observed across Europe over the last three
decades.
The declines in mortality rates could be explained by
earlier diagnosis and mostly access to better management of the
cases.
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Fig. 2. Age-standardized (direct method, world standard population) breast cancer
mortality rates *, all ages, for each patterny identiﬁed.
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no longer increasing or even declining in some settings and
speciﬁc age-groups,3,32 in all the European countries analysed,
incidence is still increasing, or not varying signiﬁcantly, in the age
groups with the largest contribution to the overall rates. These
trends are largely inﬂuenced by diagnosis and screening prac-
tices; estimates of excess incidence due to screening range from
11e19%33 to 15e25%.34,35 Furthermore, these trends depend on
the frequency and changes of risk factors such as early menarche,
delayed childbearing, lower parity, use of postmenopausal hor-
mone therapy and obesity.36,37 Most of these risk factors are still
more common in more afﬂuent settings and are increasing in the
less afﬂuent.38 This is in accordance with the observation of the
highest ASIR in the countries included in pattern 1, the one pre-
senting the highest median GDP, and the lowest ASIR in the less
afﬂuent countries from pattern 3.
In pattern 3 (excluding Finland, France, Greece and Sweden),
although the inﬂection in the mortality rates occurred later than in
the remaining countries, the ASMR peaked at lower values. Also, in
pattern 2 the decline started later and at lower ASMR than that* We considered the existence of organized screening, regardless of its coverage or participation rates.
† The results referring to pattern 3 do not include data from Finland, France, Greece or Sweden.
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Fig. 3. Proportion of countries with no organized breast cancer screening, or screening
programmes set up in different time periods*, for each pattern identiﬁed.observed for pattern 1. These distinctive features suggest that the
implementation of effective cancer control measures occurred in
different times in settings with different risk proﬁles for breast
cancer.
The best estimates of the impact of screening mammography
on breast cancer mortality range from 10% on regional mortality
data,39 to 20% on trial results.33 Since the fall in mortality in
pattern 1 exceeded 30%, this indicates that most of the decline is
due to improved management and treatment. Also, in most of
the countries considered in our analyses the lag between onset of
screening and the inﬂection of the mortality trends was shorter
than the 7e12 years that could be expected40 if the screening
programmes had an important contribution to the initial de-
clines. However, no inference is possible regarding their longer
term effects on mortality. Furthermore, these results do not
exclude the potential contribution of opportunistic screening for
the mortality reduction. In most of the countries from patterns 1
and 2 and in the more afﬂuent from pattern 3, the incidence
rates increased more steeply in the age-groups eligible for
screening, suggesting that mammography screening was wide-
spread, to higher or lesser extent, even in the absence of
screening programmes. In fact, countries with no programmes
implemented or with lower participation rates are known to
have a considerable volume of “opportunistic” mammography
testing, namely Belgium, Czech Republic, France, Germany,
Hungary, Italy, Malta and Switzerland.29,41e43 Although the bal-
ance between beneﬁts and risks of screening is less favourable in
opportunistic mammography testing than in organized pro-
grammes,44,45 the former may also have a favourable impact on
mortality.46
There has been a substantial improvement in breast cancer
treatments since the 1960’s, when radical mastectomy only was the
predominant treatment option.47 By the late 1980’s, in many
developed countries tamoxifen and polychemotherapy were used
as adjuvant therapy after surgical treatment for primary breast
cancer; therefore, an effect in mortality trends should occur by
early 1990’s,48 which makes the declining mortality trends expe-
rienced in several countries compatible with the increase in use of
systemic adjuvant therapies. The current therapies, more effective
and more age- and tumour-speciﬁc,8,11 as well as the integrated
organization of the provision of breast cancer care36 contributed to
a sustained decline in mortality rates in the last two decades,
especially in countries in patterns 1 and 2.
Between 1980 and 2010, three different revisions of the Inter-
national Classiﬁcation of Disease (ICD) were used to code the un-
derlying cause of death. Although changes in coding could induce
some variation of rates, it is not likely to compromise the compa-
rability of data over time, since differences between revisions are
minor regarding breast cancer.49,50
Our study relied on an original approach to summarize the
trends in cancer mortality rates in different countries. Model-based
clustering has several advantages over standard cluster approaches.
It provides cluster solutions with ten different covariance struc-
tures, while the most popular heuristic clustering methods (Ward’s
and K-means) only allow one type covariance structure,20 and also
allows the choice of the model and the number of clusters to be
recast as statistical model choice problems based on information
criteria.
Based on the BIC the 7-cluster solutionwas the best, followed by
the 2- and 3-cluster solutions, with similar BIC values. When seven
clusters were considered, six of these clusters included only 3 or 4
countries, and were considered too speciﬁc to constitute a general
pattern. Between the 2- and 3-cluster solutions we opted for the
latter, because it yielded groups of countries clearly more
J. Amaro et al. / The Breast 22 (2013) 244e253250homogeneous regarding the patterns of variation in breast cancer
mortality.
The reliability of the model-based clustering was evaluated by
tenfold cross validation.51 The sample was divided in ten parti-
tions, and each of the subsets of nine out of the ten partitions was
used to ﬁt ten different models (data not shown). The agreement
between the predictions from these models and those from the
model based on the complete dataset was moderate52
(kappa ¼ 0.55). This, reﬂects the fact that some countries depict
a pattern of variation that does not ﬁt so well in the main patterns,
as described for Finland, France, Greece and Sweden (after
excluding these four countries the kappa increased to 0.61),
although some misclassiﬁcation may be anticipated for other
countries (e.g. Poland). Furthermore, the 4-cluster solution did not
accommodate the countries that were a bad ﬁt for pattern 3 in the
additional pattern, which supports our option for only 3 main
clusters that reﬂect quite closely the trends in the majority of the
European countries analysed.
Despite the limitations described above, the fact that this model
provides an unconstrained analysis of mortality patterns is one of
the major strengths of this paper. Our study adds to previous
research on this topic the identiﬁcation of three clusters of countries
that are homogeneous regarding the variation in breast cancer
mortality, while remaining heterogeneous regarding the distribution
of variables traditionally used for an a priori grouping of the coun-
tries, namely geographical region, economic development or stan-
dards of care. Although Northern European, Southern European and
Eastern European countries are predominant in patterns 1, 2 and 3,
respectively, all clusters include countries from different European
regions. The median GDP and the proportion of countries with_____ Observed rates (1980-2010)     _
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SWE UKRorganized screening decreases from pattern 1 to 3, but there is a
clear overlap of the distribution of these variables across patterns,
especially between patterns 1 and 2.
We used incidence data obtained from the CI5plus database to
ensure some homogeneity of data quality. However, these data are
based on a coverage of less than 15% of the country population
from Austria, France, Germany, Italy, Netherlands, Poland, Spain
and Switzerland.53 Since incidence data was used mainly to
interpret the patterns, this has not compromised the validity of our
ﬁndings.
In conclusion, this study provides a general model for the
description and interpretation of the variation in breast cancer
mortality in Europe, based in three main patterns.Conﬂict of interest statement
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standardized mortality rates (direct method, World standard
population), all ages.____ Estimated rates (1980-2010)
d; CZE=Czech Republic; DEU=Germany; DNK=Denmark; ESP=Spain; 
ece; HRV=Croatia; HUN=Hungary; IRL=Ireland; ISL=Island; ITA=Italy; 
a; MLT=Malta; NLD=The Netherlands; NOR=Norway; POL=Poland; 
E=Sweden; UKR=Ukraine.
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Appendix 2. Identiﬁcation of the patterns by model-based
clustering.
Appendix 3. Characterization of countries regarding
organized screening activities, by patterns of trends in breast
cancer mortality rates.
Country Organized screening
Year ﬁrst
programme
started
National
coverage
(year)
Age group
(years)
References
Pattern 1 Belgium 2001 Yes 50e69 29
Denmark 1991 No 50e59 29,54,55
Ireland 2000 Yes 50e64 56e58
Luxembourg 1992 Yes 50e69 29
Malta e No e 41,59
Netherlands 1989 Yes (1997) 50e69/75a 29,60
Scotland (UK) 1988 Yes (1991) 50e64/70b 30
England (UK) 1988 Yes (1995) 50e64/70c 61
Switzerland 1999d No 50e70 29,44,59,62
Pattern 2 Austria 2008e No 50e69 63,64
Czech
Republic
2002 Yes 45e69f 41,43,59
Germany 2005 2009 50e69 29,41,65
Hungary 2002g Yes 45e65 41,66
Italy 1985 No 45/50e69h 29,31,65,67
Norway 1996 2004 50e69 29,68
Portugal 1990 No 45e69 29
Spain 1990 2000 45/50e64/69i 69
(continued on next page)
(continued )
Country Organized screening
Year ﬁrst
programme
started
National
coverage
(year)
Age group
(years)
References
Slovenia e No e 33
Pattern 3 Belarus e No e 70
Bulgaria e No e 23,29,32
Croatia 2006 Yes 50e69 71,72
Estonia 2003 Yes 50e59 59
Finland 1987 Yes 50e59 29,73
France 1989 2004 50e74 29,74
Greece 2004 No 40-69 29,75
Latvia e No e 59
Lithuania 2006 Yes 50e69 56,59
Poland 2007 Yes 50e69 56,59
Rep. of
Moldova
e No e e
Romania e No e 59
Russian Fed. e No e e
Sweden 1986 1997 40/50e69/74j 29,56,76
Ukraine e No e e
a Women eligible in the Netherlands: 50e69 years; 70e75 included since 1998.
b Women eligible in Scotland: 50e64 years; extended to 70 in 2003/04.
c Women eligible in the United Kingdom: 50e64 years; by 2005women aged 50e
70 years were being screened.
d A pilot programme started in Switzerland in 1993 in canton Vaud.
e Tyrol (Austria): spontaneous mammography screening has an overall partici-
pation of 75% and was set up around 1993; in 2008 an organized programme started
comprising the whole state.
f Women eligible in Czech Republic: since 2010 there is no upper age limit.
g Hungary: a pilot breast screening programme was established in 1995.
h Women eligible in Italy: 50e69 years; several programmes include women over
70 and some invite women 45e49 years.
i Women eligible in Spain: 50e65 years; some regions include women up to 69
and some invite women over 45 years.
j Women eligible in Sweden: 100% of counties invite 50e69 years; 60e70% start
at age 40 and approximately 50% of counties invite age group 70e74.
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